Dunad Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$24.1M
- Investors
-
7
Dunad Therapeutics General Information
Description
Developer of a proprietary tunable covalent chemistry platform designed to discover and develop medicines that selectively and durably target disease drivers. The company combines a deep understanding of disease biology with advanced chemistry to modulate protein stability and conformation, enabling pharmaceutical companies to create targeted therapies.
Contact Information
Website
www.dunadtx.comCorporate Office
- The Officers Mess
- Royston Road
- Cambridge CB22 4QH
- England, United Kingdom
Corporate Office
- The Officers Mess
- Royston Road
- Cambridge CB22 4QH
- England, United Kingdom
Dunad Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC | 02-Nov-2021 | $24.1M | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC (Series A) | 24-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Feb-2020 | Completed | Pre-Clinical Trials | |||
| 1. University Spin-Out | 01-Jan-2020 | Completed | Startup |
Dunad Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Ordinary 2 | ||||||||
| Series A | 1,000,000 | $0.001369 | $6.85 | $6.85 | $6.85 | 56.94% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Dunad Therapeutics Patents
Dunad Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026136220-A1 | Combination therapies with pikfyve kinase inhibitors | Pending | 16-Dec-2024 | ||
| WO-2026136219-A1 | Pikfyve assay | Pending | 16-Dec-2024 | ||
| US-20260274825-A1 | Pikfyve kinase inhibitors | Pending | 16-Dec-2024 | ||
| WO-2026136226-A1 | Pikfyve kinase inhibitors | Pending | 16-Dec-2024 | ||
| WO-2026136228-A1 | Pikfyve kinase inhibitors | Pending | 16-Dec-2024 | C07D403/14 |
Dunad Therapeutics Signals
Dunad Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alpha Wave Global | Growth/Expansion | Minority | ||
| BioGeneration Ventures | Venture Capital | Minority | ||
| Novartis | Corporation | Minority | ||
| Wellington Partners | Venture Capital | Minority | ||
| Epidarex Capital | Venture Capital | Minority |
Dunad Therapeutics FAQs
-
When was Dunad Therapeutics founded?
Dunad Therapeutics was founded in 2020.
-
Where is Dunad Therapeutics headquartered?
Dunad Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Dunad Therapeutics?
Dunad Therapeutics has 12 total employees.
-
What industry is Dunad Therapeutics in?
Dunad Therapeutics’s primary industry is Drug Discovery.
-
Is Dunad Therapeutics a private or public company?
Dunad Therapeutics is a Private company.
-
What is the current valuation of Dunad Therapeutics?
The current valuation of Dunad Therapeutics is .
-
What is Dunad Therapeutics’s current revenue?
The current revenue for Dunad Therapeutics is .
-
How much funding has Dunad Therapeutics raised over time?
Dunad Therapeutics has raised $31.1M.
-
Who are Dunad Therapeutics’s investors?
Alpha Wave Global, BioGeneration Ventures, Novartis, Wellington Partners, and Epidarex Capital are 5 of 7 investors who have invested in Dunad Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process